Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 9/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.49 |
| ▸ | AR | P10275 | 6/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | F11 | P03951 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29465757 | 0.89 | LPL (0.47) | LPLLIPGF2F11PRSS1 | |
| SCHEMBL4426051 | 0.89 | LPL (0.47) | LPLLIPGF2F11PRSS1 | |
| SCHEMBL29847114 | 0.87 | LPL (0.46) | LPLLIPGF2F11PRSS1 | |
| SCHEMBL21853794 | 0.87 | LPL (0.46) | LPLLIPGF2F11PRSS1 | |
| SCHEMBL321493 | 0.87 | LPL (0.49) | LPLLIPGF2F11PRSS1 | |
| SCHEMBL30692214 | 0.86 | LPL (0.47) | LPLLIPGF2F11PRSS1 | |
| SCHEMBL26923911 | 0.86 | LPL (0.47) | LPLLIPGF2F11PRSS1 | |
| SCHEMBL20875541 | 0.84 | LPL (0.46) | LPLLIPGF2F11PRSS1 | |
| SCHEMBL19031772 | 0.83 | LPL (0.45) | LPLLIPGF2F11PRSS1 | |
| SCHEMBL18530597 | 0.83 | LPL (0.45) | LPLLIPGF2F11PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3398945-B1 | PYRIMIDINYL DERIVATIVES AND THEIR USE IN OPTOELECTRONIC DEVICES | SAMSUNG DISPLAY CO LTD (KR) | 2022-11-02 | — | — | EP | disclosed |
| EP-3392247-B1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2020-07-29 | — | — | EP | disclosed |
| EP-3459943-B1 | PYRIMIDINE-BASED ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2020-07-22 | — | — | EP | disclosed |
| EP-3459943-B1 | PYRIMIDINE-BASED ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2020-07-22 | — | — | EP | disclosed |
| US-10668067-B2 | Pyridine sulfonamides | AMGEN INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190201404-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2019-07-04 | — | — | US | disclosed |
| US-20190167682-A1 | PYRIDINE SULFONAMIDES | AMGEN INC. (US) | 2019-06-06 | — | — | US | disclosed |
| US-10278972-B2 | Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2019-05-07 | — | — | US | disclosed |
| EP-3459943-A1 | PYRIMIDINE-BASED ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2019-03-27 | — | — | EP | disclosed |
| EP-3459943-A1 | PYRIMIDINE-BASED ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2019-03-27 | — | — | EP | disclosed |
| US-6683097-B2 | AFFINITY TO NMDA (N-METHYL-D-ASPARTATE)-RECEPTOR SUBTYPE SELECTIVE BLOCKERS; MEDIATING PROCESSES UNDERLYING DEVELOPMENT OF CENTRAL NERVOUS SYSTEM AS WELL AS LEARNING AND MEMORY FORMATION | HOFFMANN-LA ROCHE INC. | 2004-01-27 | — | — | US | disclosed |
| US-6667335-B2 | NMDA (N-methyl-D-aspartate)-receptor subtype selective blockers | HOFFMANN-LA ROCHE INC. | 2003-12-23 | — | — | US | disclosed |
| US-20030229096-A1 | Substituted imidazol-pyridazine derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2003-12-11 | — | — | US | disclosed |
| WO-2003097637-A1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-27 | — | — | WO | disclosed |
| EP-1358165-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| US-20030191311-A1 | A 5-(imidazol-1-yl-methyl)-pyridine derivatives for treating an NMDA-receptor-mediated disease, neurodegeneration disorder caused by stroke or brain trauma, Alzheimer's disease, Parkinson's disease, Huntington's disease | EVOTEC INTERNATIONAL GMBH (DE) | 2003-10-09 | — | — | US | disclosed |
| US-20030187268-A1 | Imidazole derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
| US-6610723-B2 | Such as 3-(3,4-dimethyl-phenyl)-5-(2-methyl-imidazol-1-yl-methyl)-pyridine having affinity to N-methyl-D-aspartate-receptor subtype selective blockers; central nervous system; learning, memory, neurodegeneration | HOFFMANN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020151715-A1 | Imidazole derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2002060877-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191311-A1 | A 5-(imidazol-1-yl-methyl)-pyridine derivatives for treating an NMDA-receptor-mediated disease, neurodegeneration disorder caused by stroke or brain trauma, Alzheimer's disease, Parkinson's disease, Huntington's disease | GRIN1, GRIN2B, GRIN3B | LPL 4442/4885LIPG 4647/4885AR 3226/4885 |
| US-20020151715-A1 | Imidazole derivatives | GRIN2B, GRIN1, GRIN2A | LPL 4830/4885LIPG 4752/4885AR 4428/4885 |
| US-10278972-B2 | Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | TYMS, TYMP, TPX2 | LPL 4515/4885LIPG 4399/4885AR 2623/4885 |
| US-20190167682-A1 | PYRIDINE SULFONAMIDES | TRPV1, TRPA1, TRPV5 | LPL 4322/4885LIPG 4663/4885AR 3643/4885 |
| US-10668067-B2 | Pyridine sulfonamides | TRPV1, TRPA1, TRPV5 | LPL 4322/4885LIPG 4663/4885AR 3643/4885 |
| US-20190201404-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TYMS, TYMP, TPX2 | LPL 4515/4885LIPG 4399/4885AR 2623/4885 |
| US-20030229096-A1 | Substituted imidazol-pyridazine derivatives | GRIN2B, GRIN2A, GRIN2C | LPL 4626/4885LIPG 4808/4885AR 599/4885 |
| US-20030187268-A1 | Imidazole derivatives | GRIN2B, GRIN1, GRIN2A | LPL 4830/4885LIPG 4752/4885AR 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.